Login to Your Account

Rydapt ratified: Novartis' targeted AML therapy wins FDA approval

By Michael Fitzhugh
Staff Writer

Friday, April 28, 2017

FDA approval has arrived for Novartis AG's Rydapt, a breakthrough-designated treatment for adults with newly diagnosed FLT3-mutated acute myeloid leukemia (AML).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription